Dr. Pant is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Oklahoma City, OK 77030Phone+1 405-271-8299
Education & Training
- Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2005 - 2008
- University of Oklahoma Health Sciences CenterResidency, Internal Medicine, 2002 - 2005
- Maulana Azad Medical CollegeClass of 2001
Certifications & Licensure
- FL State Medical License 2021 - Present
- AZ State Medical License 2023 - 2026
- GA State Medical License 2023 - 2026
- TN State Medical License 2023 - 2026
- TX State Medical License 2015 - 2026
- LA State Medical License 2023 - 2025
- MS State Medical License 2023 - 2025
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Clinical Trials
- Cytogenetic Studies in Acute Leukemia and Multiple Myeloma
- Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2005 Nov 01
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer Start of enrollment: 2006 Sep 26
- Join now to see all
Publications & Presentations
PubMed
- ASO Visual Abstract: Improved Outcomes Following Resection of Perihilar Cholangiocarcinoma-A 27-Year Experience.Anish J Jain, Mateo Lendoire, Antony Haddad, Ching-Wei D Tzeng, Artem Boyev
Annals of Surgical Oncology. 2025-03-25 - Incorporating Circulating Tumor DNA Testing Into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group.Lakshmi Rajdev, Gentry G King, Christopher H Lieu, Stacey A Cohen, Shubham Pant
JCO Precision Oncology. 2025-03-01 - A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3).Zev A Wainberg, Davide Melisi, Teresa Macarulla, Roberto Pazo Cid, Sreenivasa R Chandana
Future Oncology. 2025-03-01
Journal Articles
- Response and Survival Associated with First-Line FOLFIRINOX vs Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal AdenocarcinomaShubham Pant, Milind Javle, Naruhiko Ikoma, Ching-Wei Tzeng, Jeffrey E Lee, JAMA Surgery
Lectures
- Tyme-88-Panc Part 2: A randomized phase II/III of SM-88 with MPS as third-line in metastatic PDAC.ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
- A phase I dose escalation (DE) study of ERK inhibitor, LY3214996, in advanced (adv) cancer (CA) patients (pts).2019 ASCO Annual Meeting - 6/1/2019
- A phase I/II study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients who have progressed on prior anti-PD-1 therapy.2019 ASCO Annual Meeting - 6/1/2019
- Join now to see all
Other
- Evaluation and management of aromatase inhibitor-induced bone lossPant S, Shapiro CL
http://www.uptodate.com/contents/evaluation-and-management-of-aromatase-inhibitor-induced-bone-loss
UpToDate, Wolters Kluwer Health - 2012-08-29
Authored Content
- Response and Survival Associated with First-Line FOLFIRINOX vs Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal AdenocarcinomaJuly 2020
- Response and Survival Associated with First-Line FOLFIRINOX vs Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal AdenocarcinomaJuly 2020
Press Mentions
- mRNA Vaccines Show Promise in Pancreatic Cancer in Early TrialFebruary 19th, 2025
- 11 New Research Advances from the Past YearDecember 19th, 2024
- Exploring Pancreatic Cancer Vaccines: What’s Next?November 21st, 2024
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: